(Press-News.org) Prostate cancer is a leading cause of death among American men, and it’s resistant to one of the most powerful chemotherapy medications — cisplatin. Now, researchers reporting in ACS Central Science have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases cisplatin into the weakened cells, causing them to die. In mouse models, an orally administered version shrunk tumors substantially.
Cisplatin attacks testicular, breast, bladder, lung and ovarian cancer cells, damages their DNA and effectively destroys tumors. However, it’s not effective against prostate cancer for reasons that are unclear to scientists, and many advanced cases of the disease don’t respond to other therapies, such as androgen deprivation. Previously, researchers have shown in mouse models that as the disease advances, tumor cells shift from glycolysis toward fatty acid oxidation to support their growth and division. So, Shanta Dhar and colleagues from Sylvester Comprehensive Cancer Center at the University of Miami wanted to develop a therapy that would inhibit fatty acid oxidation in cancer cells by targeting a mitochondrial protein that is vital to the metabolic process, making the cells susceptible to cisplatin.
The researchers verified that human prostate cancer cells thrive using fatty acid oxidation by assessing the biopsies of 38 people with the disease. Then they screened several cisplatin-containing prodrug compounds, which release the platinum-based molecule when they’re broken down, to see if they could inhibit fatty acid oxidation. The cisplatin prodrug Platin-L, which has a cisplatin molecule bound to a 12-carbon fatty acid on one side and succinate on the other side, had the greatest effect by binding to a key protein required for long chain fatty acid transport, a primary step in this metabolic process. And in trials, Platin-L reduced the growth of prostate cancer cells by over 50% in several different cell lines.
To develop a treatment that could be taken orally, the researchers encapsulated Platin-L in nanoparticles made with a biocompatible polymer that targeted prostate cancer cells. They administered the nanoparticles to mouse models with cisplatin-resistant prostate cancer and observed that the tumors shrunk, whereas tumors in animals treated with saline or cisplatin grew. Additionally, the Platin-L nanoparticle-treated mice had steady body weight, increased survival rates and didn’t display peripheral neuropathy. Because the treatment affects fatty acid metabolism, which can be elevated in other types of cancers, the researchers say their type of additive Platin-L therapy may also be applicable to additional aggressive and chemotherapy-resistant cancers.
The authors acknowledge funding from the Sylvester Comprehensive Cancer Center, a Bankhead-Coley Grant from the Florida Department of Health and the U.S. National Institutes of Health.
The paper’s abstract will be available on July 12 at 8 a.m. Eastern time here: http://pubs.acs.org/doi/abs/10.1021/acscentsci.3c00286
For more of the latest research news, register for our upcoming meeting, ACS Fall 2023. Journalists and public information officers are encouraged to apply for complimentary press registration by completing this form.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Follow us: Twitter | Facebook | LinkedIn | Instagram
END
A step toward treating chemotherapy-resistant prostate cancer
2023-07-12
ELSE PRESS RELEASES FROM THIS DATE:
A new tactic to take on leprosy
2023-07-12
Leprosy has existed since at least Biblical times, yet scientists still don’t know exactly how Mycobacterium leprae causes the disease’s symptoms. Though antibiotics can treat the illness, researchers are concerned about the increase in drug-resistant strains. Now, a team reporting in ACS Central Science has begun to understand the unique role certain immune receptors play in leprosy infections in mice, which could lead to new types of treatments for this disease and others in humans.
Thousands of people are currently affected by leprosy — also known as Hansen’s disease — according to the World Health Organization. The disease can cause skin ...
Ohio train derailment, clean-up resulted in high levels of some gases, study shows
2023-07-12
A freight train carrying industrial chemicals derailed near East Palestine, Ohio, in February 2023, and to avoid explosions, authorities conducted a controlled release and burned the cars’ contents. Residents were worried about their health and the environment, so researchers have been assessing the local air quality with stationary and mobile sampling methods. Now, in ACS’ Environmental Science & Technology Letters, they report that some gases, including acrolein, reached levels that could be hazardous.
After the derailment, disaster response teams ...
EMBARGOED: In preclinical study, Sylvester researchers target treatment-resistant prostate cancer with oral chemotherapy that works 2 ways
2023-07-12
MIAMI, FLORIDA (EMBARGOED UNTIL JULY 12, 2023, AT 8AM ET) – Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a first-of-its-kind, orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells.
They validated their targets in human prostate cancer biopsies, tested the new approach in human cancer cells and a mouse model ...
2018–2022 Southern Resident killer whale presence in the Salish Sea: continued shifts in habitat usage
2023-07-12
Monika Wieland Shields, Director of the Orca Behavior Institute, has observed orcas in the Salish Sea, a marginal sea of the Pacific Ocean located in the Canadian province of British Columbia and the U.S. state of Washington, since 2000. She has recently published an article in the peer-reviewed Open Access journal PeerJ Life & Environment that provides crucial insights into the changing habitat usage of the critically endangered Southern Resident killer whales (Orcinus orca), shedding light on historic trends and the current status of the population in the Salish Sea. ...
$3.9M grant funds e-cigarette flavoring research at Ohio State’s Center for Tobacco Research
2023-07-12
COLUMBUS, Ohio - A new $3.9 million grant from the U.S. Food and Drug Administration (FDA) will allow researchers with the Center for Tobacco Research at The Ohio State University Comprehensive Cancer Center to evaluate effects of e-cigarette flavors on the smoking behaviors of current adult smokers.
The study, co-led by Theodore Wagener, PhD, director of Ohio State’s Center for Tobacco Research, and Tracy Smith, PhD, of the Medical University of South Carolina (MUSC) Hollings Cancer Center, will be the first ...
Gut bacteria linked to fatty deposits in heart arteries
2023-07-12
In a major Swedish study, researchers have discovered a link between the levels of certain bacteria living in the gut and coronary atherosclerotic plaques. Such atherosclerotic plaques, which are formed by the build-up of fatty and cholesterol deposits, constitute a major cause of heart attacks. The study was led by researchers at Uppsala and Lund University and the findings have now been published in the scientific journal Circulation.
The new study was based on analyses of gut bacteria and cardiac imaging among 8,973 participants aged 50 to 65 from Uppsala and Malmö without previously known heart disease. They were all ...
Study reveals new mechanism for rapid evolution of multi-drug resistant infections in patients
2023-07-12
Findings challenge the traditional view that antimicrobial resistance (AMR) emerges from pathogens that acquire new mutations
Samples from ICU patients suggest that instead, highly diverse pathogen communities harbour pre-existing resistant genotypes
The results suggest that interventions aimed at limiting the spread of bacteria between patients may provide a powerful approach to combat AMR.
A research study led by the University of Oxford provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections. The findings, published today in the journal ...
Blood pressure patterns in the first half of pregnancy improve early prediction of preeclampsia and gestational hypertension
2023-07-12
Routine blood pressure readings recorded in the first half of pregnancy can be divided into 6 distinct patterns that can effectively stratify patients by their risk of developing preeclampsia and gestational hypertension later in pregnancy, Kaiser Permanente researchers found.
The study, published July 12 in the Journal of the American Heart Association, showed that 6 pregnancy blood pressure trajectories seen within the first 20 weeks of pregnancy along with clinical, social, and behavioral risk factors can accurately predict and stratify risk of preeclampsia and gestational hypertension in low- to moderate-risk patients. ...
Gulf War illness caused by mitochondrial dysfunction, not inflammation
2023-07-12
Gulf War Illness (GWI) is a chronic multisymptom health condition affecting one-third of all veterans who served in the 1991 Gulf War, most of whom remain afflicted more than 30 years later. Common symptoms include fatigue, headaches, muscle aches, joint pain, diarrhea, insomnia and cognitive impairment.
The condition is believed to have been triggered by veterans’ exposure to environmental toxins. However, its exact mechanism in the body continues to be debated, making it difficult to diagnose and treat. The prevailing ...
Queen Mary-led research uncovers why people who have Down’s Syndrome age prematurely
2023-07-12
An overdosed gene on chromosome 21 causes people with Down’s Syndrome to age faster than the general population.
The molecular processes responsible for natural ageing of cells are poorly understood. Studying conditions in humans where ageing is accelerated due to genetic causes presents opportunities to learn about the mechanisms that control ageing and devise strategies to slow down the ageing process.
Adults who have Down’s Syndrome (DS) show earlier signs of ageing-related conditions: reduction in tissue regenerative capacity, alopecia, dry skin, ...